GENEVA–(BUSINESS WIRE)–Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
Author: Business Wire
Global Optical Coherence Tomography Angiography Equipment Market to 2028 – COVID-19 Impact and Analysis – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Coherence Tomography Angiography Equipment Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type and End User” report has been added to ResearchAndMarkets.com’s offering. The optical coherence tomog…
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
NEW YORK & FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #CSTL–Research to Prevent Blindness and Castle are partnering to increase opportunities for medical students to gain research experiences in ocular cancer.
Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides an…
Steven C. Glass Named Medical Mutual’s Next CEO and President
CLEVELAND–(BUSINESS WIRE)–Bob King, Lead Director of Medical Mutual’s board of directors, today announced that Steven (Steve) C. Glass will succeed Rick Chiricosta as CEO and President of Medical Mutual of Ohio. Mr. Glass will also take a seat on Med…
Ocular Hypertension Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive inform…
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Resumen: El Reino Unido es el primer país en conceder la licencia para Ongavia (ranibizumab)▼, el biosimilar oftalmológico de Teva
ÁMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd aprecia la decisión de la Medicines & Healthcare Regulatory Agency (MHRA), la agencia reguladora de medicamentos y productos sanitarios del Reino Unido, de conceder una licencia para On…
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today reported that a post-hoc analysis using computer automated grading of digital photography from the completed Phase 3 TRANQUILITY dry eye chamber trial demonstr…
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101
WELLESLEY, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc. (the “Company” or “Qlaris”), a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, today announced results from QC-201, a first-in-human, Phase 2 clinical trial of QL…
Riassunto: Il Regno Unito è il primo paese a concedere una licenza per il biosimilare oftalmico di Teva, Ongavia (ranibizumab)▼
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd valuta favorevolmente la decisione dell’Agenzia dei medicinali e dei prodotti sanitari del Regno Unito (MHRA) di concedere una licenza per Ongavia®, un biosimilare di Lucentis® (ranibizumab…
Première licence accordée au Royaume-Uni pour le biosimilaire ophtalmologique de Teva, Ongavia (ranibizumab)▼
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd se réjouit de la décision de l’Agence britannique de réglementation des médicaments et des soins de santé (MHRA) de délivrer une licence pour Ongavia®, un biosimilaire à injection oculaire …
Großbritannien erteilt als erstes Land eine Zulassung für das ophthalmologische Biosimilar Ongavia (Ranibizumab) von Teva▼
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. begrüßt die Entscheidung der britischen medizinischen Zulassungs- und Aufsichtsbehörde für Arzneimittel (Medicines & Healthcare Regulatory Agency, MHRA), eine Lizenz für Ongavia®, ein …
Samenvatting: Verenigd Koninkrijk verleent als eerste licentie voor Teva’s oogheelkundige biosimilar Ongavia (ranibizumab)▼
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd verwelkomt het besluit van de Britse Medicines & Healthcare Regulatory Agency (MHRA) om een licentie te verlenen voor Ongavia®, een biosimilar van Lucentis® (ranibizumab), een ooginject…
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom …
Health Leaders Urge Immediate Action on Patient and Workforce Safety
BOSTON–(BUSINESS WIRE)– #AHRQ–IHI, CMS, CDC, and AHRQ representatives announce Declaration to Advance Patient Safety, on behalf of an IHI-convened National Steering Committee.
Sunvera Group Forms New Partnership With William S. Goldstein, MD PC – Laser Eye Care Center
BINGHAM FARMS, Mich.–(BUSINESS WIRE)–Sunvera Group has formed a new partnership with William S. Goldstein, MD PC in Shelby Township, expanding their network across Michigan and Ohio.
Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio announced that Pravin U. Dugel, M.D., President, will present a corporate overview at the H.C. Wainwright Global Investment Conference.
Warby Parker Announces First Quarter 2022 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2022. “Our team has a lot to be proud of …